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Background. Good postoperative analgesic management improves maternal satisfaction and care of the neonate. Postoperative
pain management is a challenge in Mulago Hospital, yet ketamine is accessible and has proven benefit. We determined ketamine’s
postoperative analgesic effects. Materials and Methods. We did an RCT among consenting parturients that were randomized to
receive either intravenous ketamine (0.25mg/kg) or placebo after spinal anesthetic. Pain was assessed every 30mins up to 24
hours postoperatively using the numerical rating scale. The first complaint of pain requiring treatment was noted as “time to first
breakthrough pain.” Results. We screened 100 patients and recruited 88 that were randomized into two arms of 44 patients that
received either ketamine or placebo. Ketamine group had 30-minute longer time to first breakthrough pain and lower 24-hour pain
scores. Postoperative diclofenac consumption was lesser in the ketamine group compared to placebo and Kaplan-Meier graphs
showed a higher probability of experiencing breakthrough pain earlier in the placebo group. Conclusion. Preincision intravenous
ketamine (0.25mg/kg) offered 30-minute prolongation to postoperative analgesia requirement with reduced 24-hour pain scores.
We recommend larger studies to explore this benefit. This trial is registered with Pan African Clinical Trial Registry number
PACTR201404000807178.
1. Introduction
Pain is a subjective and multidimensional experience often
inadequately managed in medical practice [1], with a USA
survey reporting a 50–70% likelihood of experiencing mod-
erate to severe postoperative pain due to inadequate pain
management [2]. Good postoperative pain control improves
maternal satisfaction and baby care, decreases morbidity [3,
4], and is desired to increase mobility which reduces the
incidence of deep vein thrombosis [5]. In a low resource
setting like Uganda, the National Referral and Teaching
Hospital, Mulago, (MNRTH) faces profound challenges,
for example, overwhelming patient numbers and anecdotal
clinical staff shortages with a nurse: patient ratio of 1 : 40
[6]. Only forty-five percent (45%) of anesthesia providers
have full-time access to pethidine or morphine while twenty-
one percent (21%) have no complete access to these drugs
[7].
Ketamine is an N-methyl-D-aspartate (NMDA) receptor
antagonist that produces analgesia by desensitization of sensi-
tized NMDA receptors, thereby inhibiting pain transmission
in the CNS [8, 9]. In subanesthetic doses, it has been shown
to reduce first 24 hours analgesic requirements after surgery
with decreased postoperative opioid requirements in elective
Caesarean section patients [10, 11]. Also for chronic pain it
is a “third line” treatment where conventional treatments
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have failed [12]. Ketamine is safe for use in late pregnancy
and for neonates and studies done in Africa have shown
that it reduced morphine requirement after delivery among
parturients [13]. It was recently cleared for use in brain
injury patients based on its stable hemodynamic profile and
beneficial bronchodilating respiratory properties, which has
led to increased clinical use especially in severe asthma
treatment [14].
We hypothesized that nonsedating dose of 0.25mg/kg
of preincision ketamine would prolong the time to pain
requiring treatment, based on ketamine’s beneficial proper-
ties above and especially since studies showed its benefit as
an adjuvant for postoperative analgesia in low-dose regimens
ranges of 0.25–0.5mg/kg [15]. We chose a randomized
prospective controlled trial setting to study the twenty-
four-hour (24-hour) postoperative analgesia effects when
administered at preincision for elective Caesarean delivery
performed under spinal anesthesia.
2. Materials and Methods
This study was approved by the Makerere University, School
of Medicine Research and Ethics Committee (SOMREC),
and was registered to the Pan African Clinical Trial Registry
with identifier number PACTR201404000807178. This was
a prospective, randomized, double-blind, placebo-controlled
trial conducted from January to March 2014 at MNRTH,
which is a 1500-bed capacity that receives on average 48,000
patients annually at its Accident and Emergency (A&E). The
labor suit conducts 32,000 deliveries annually with Caesarean
sections accounting for 15–20% [16].
Eligible patients due for elective Caesarean section under
spinal anesthesia were taken through consent process and
enrolled after getting written consent. Our inclusion criteria
included parturients scheduled for elective Caesarean section
with American Society of Anesthesiologists (ASA) physical
statuses I and II. Exclusion criteria were patients with hyper-
tension, hypersensitivity to ketamine or its preservatives,
ASA class > II, psychiatric disease, those who received
chronic opioid therapy, and also those who required conver-
sion from spinal to general anesthesia.
Sample size was calculated based on a power of 80% and
standard deviation of 25 from study by Menkiti et al. [17]
who used a ketamine dose of 0.15mg/kg and noticed lower
postoperative pain scores in the ketamine group, with the





), at 120 minutes. This gave us a total patient estimate
(𝑁) of eighty-eight (88) patients with forty-four (44) in each
arm of the study.
2.1. Randomization and Concealment. Block randomization
with a block of 4 was used to randomly assign participants to
receive either ketamine or placebo in equal numbers for the
two groups. A computer program was used to generate the
randomization sequence by an independent statistician.
The ketamine group received intravenous ketamine
(0.25mg/kg) and the placebo group received normal saline
and blinding for both participants and study investigatorswas
achieved by use of 10mL syringes of similar appearance and
consistency. The placebo was 10mL of normal saline while
ketamine was diluted to make 10mL of 5mg/mL solution.
All syringes had 5mg/mL colorless solution that catered for
a lowest possible adult weight of 40 kg and a highest weight
being 200 kg.
Concealment. Concealment was achieved bymaking sure that
each syringe was labelled according to sequence-generated
codes earlier presented as a list of sequential random treat-
ment codes. The labelled syringes were brought in an opaque
carrier envelope to the operating theatre and handed to
the principle investigator every morning in the presence
of a theatre nurse and study investigator. At the theatre
receiving area a syringe was retrieved with its sticker code
number, similar to computer generated number sequence,
becoming the patients study number and then patient
was weighed before transportation to the operating theatre
(OR).
2.2. Study Procedures. Patient was weighed in the OR and
received standard spinal anesthetic 2mL of 0.5% heavy
bupivacaine with 8% dextrose and 20mcg of fentanyl and
then placed supine with a left lateral tilt to achieve a sensory
block height of T6 before surgery. Oxygen at 3 L/min was
administered by nasal prongs to all patients. Immediately
before surgical incision, the study drugs were administered
as per randomized allocation of 0.05mL/kg of study-drug or
placebo as described above, followed by prophylactic intra-
venous antibiotics. Postoperative pain was assessed using the
self-reporting numeric rating scale (NRS) with a rating of
the lowest 0 = no pain, 10 = worst pain, 1–3 = mild pain,
4–6 = moderate pain, and 7–10 = severe pain. This was
monitored every 30mins for 24 hours or until first complaint
of pain called the “time to first breakthrough pain” which was
considered to be the pain requiring treatment (NRS ≥ 3). At
this point rescue analgesic was administered firstly by intra-
muscular diclofenac (75mg), then standard of care treatment,
and then tramadol as secondary or meperidine/pethidine
(100mg) as tertiary for persistent pain.
2.3. Data Management. Interviewer-administered and pre-
tested questionnaires were used for data collection. The
data was cleaned, coded, and double-entered into Epidata
version 3.1 and then exported and analyzed with STATA
Version 12 (Statacorp LP). The participants characteristics
were presented as means and accompanying standard devi-
ation for weight (kg), height (cm), and duration of surgery
(in minutes) while median with range was estimated for age
(in years) and parity as these were discreet variables. The
differences in median (range) between those randomized to
receive ketamine and those on placebo were assessed using a
Wilcoxon rank sum test, while a 𝑡-test was used to test for the
mean differences among the continuous variables. Survival
analysis using the Kaplan-Meier survival curves was used to
determine the probability of breakthrough pain between the
two randomization arms with accompanying log-rank test
to estimate the 𝑝 value. In analysis, a 𝑝 value of ≤ 0.05 was
considered statistically significant.






Enrolled (n = 88)
Analysed (n = 44)Analysed (n = 44)
Ketamine 0.25mg/kg Placebo normal saline
Allocated to intervention (n = 44)Allocated to intervention (n = 44)
Lost to follow-up (n = 0)Lost to follow-up (n = 0)
(iii) Withdrawal of consent (n = 2)
(ii) Prior H/o hypertension (n = 2)
(i) Failed spinal conversion to GA (n = 8)
Excluded (n = 12)
Assessed for eligibility (n = 100)
Figure 1: Flow chart and numerical scale.
Table 1: Patients’ demographics.
Variable Overall Randomization group 𝑝 valueKetamine Placebo
Median age in years (range) 29 (14–44) 28 (14–44) 29 (18–41) 0.76
Median parity (range) 4 (1–9) 4 (1–9) 4 (1–7) 0.55
Mean weight in Kg (SD) 67 (10.91) 67 (10.96) 67 (10.97) 0.78
Mean height in cm (SD) 160 (5.85) 160 (5.52) 160 (6.22) 0.94
Mean duration of operation in minutes (SD) 40 (12.73) 40 (13.51) 39 (12.03) 0.72
None Mild Moderate Severe
0 1 2 3 4 5 6 7 8 9 10
Figure 2: Numeric rating scale (NRS).
3. Results
3.1. Baseline Characteristics. We screened 100 participants for
this study and 12 were excluded while 88 parturients were
enrolled with 44 assigned to one of the two groups (Figure 1).
Overall, the median (range) age was 29 (14–44) years, with
a median (range) parity of 4 (1–9) as shown in Table 1. The
average (standard deviation) weight and height of enrolled
mothers were 67 kg (10.91) and 160 cm (5.85), respectively. On
average each operation took 40 minutes (12.75) with baseline
maternal demographics equally distributed in both arms.
NRS scale (Figure 2) was used to assess patients pain.
3.2. Breakthrough Pain. The median (range) time (in min-
utes) to first “breakthrough pain” among both groups was
significantly longer in the ketamine group [210 (90–270)]
when compared to those that received placebo [180 (90–360)]
with 𝑝 = 0.002. The 24-hour median (range) NRS pain
scores were higher and significant in the placebo group [5 (3–
7)] compared to the ketamine group [7 (3–9)] (𝑝 = 0.001)
(Table 2). Primary rescue analgesia dose of diclofenac was
lower in the ketamine group [used up to 75mg] in compar-
ison to the placebo [used up to 150mg] (𝑝 value = 0.053).
Secondary rescue analgesia with tramadol was equaled in
both arms and therefore not statistically significant as shown
in Figure 2 and Table 2. Eight patients (5-placebo and 3-
ketamine) required a tertiary dose of pethidine (100mg) due
to persistent pain (Figure 3). At delivery all neonates scored
APGAR 10 at 5 and 10 minutes while at study termination all
mothers and newborns were in good general condition with
stable vitals.
3.2.1. Kaplan-Meier Survival Graph. The probability of expe-
riencing earlier breakthrough pain is significantly higher
among those receiving placebo as compared to those who
received ketamine with a log-rank test 𝑝 = 0.011 (Figure 4).
This showed ketamine significantly delayed the onset of
breakthrough pain as compared to those who received
placebo.
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Time to breakthrough pain (minutes) 210 (90–270) 180 (90–360) 0.002
NRS at first breakthrough pain 5 (3–7) 7 (3–9) 0.001
Diclofenac used (mg) 75 (75–150) 150 (75–150) 0.05

















Figure 3: Graph showing postoperative analgesic drugs.
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Figure 4: Kaplan-Meier survival curve. Ketamine versus placebo
Kaplan-Meier survival estimates for breakthrough pain.
4. Discussion
We set out to determine the effects of low-dose ketamine
on postoperative course when given intravenously at prein-
cision after spinal anesthetic for Caesarean section delivery.
Our study showed that preincision IV ketamine 0.25mg/kg
prolonged first requirement of pain treatment by 30 minutes
with our ketamine group showing lower pain scores at 24
hours and also, albeit not statistically significant, had reduced
cumulative analgesic administration. This showed promise
for ketamine’s postoperative clinical benefit especially in
our resource limited setting. The first day after Caesarean
delivery is crucial for maternal-child bonding and early
initiation of breast feeding and a good long postoperative pain
window allows clinicians to start other analgesic drugs before
the anticipated onset of postoperative pain [17]. Our study
findings are similar to clinical setting studies on ketamine that
showed 10–30-minute prolongation breakthrough pain after
outpatient knee arthroscopy [18].
Ketamine was chosen because it is a readily available
drug in our setting and its multiple beneficial properties
especially its NMDA blockade aid in postoperative analgesia
based on the hypothesis that preemptive analgesia prevents
induction of central sensitization by pain inputs [19]. Surgical
tissue damage causes central pain pathway sensitization by
glutamate release that is manifested clinically as heightened
pain sensation, due to activation of postsynaptic NMDA
receptors in the spinal cord [20]. Also NMDA receptors
found both pre- and postsynaptically at pain fiber termi-
nations in the dorsal horn contribute to “wind-up,” central
sensitization plus long-term potentiation (LTP), all of which
may contribute to initiation of abnormal pain; hence NMDA
antagonists may prevent induction of central sensitization
and diminish hypersensitivity [19]. Studies fromWest Indies
showed ketamine reduced postoperative opioid requirement
with coupled improved patient satisfaction [21]; however our
study did not capture this as our local postoperative standard
of care at study timewas diclofenac followed by tramadol sec-
ondarily and then pethidine/meperidine as tertiary options
for “persistent” pain. Ketamine in subanesthetic doses offered
persistent analgesia on awakening because of its two main
active metabolites and its elimination half-life of 180 minutes
with analgesia [22]; we therefore postulated that ketamine
be used for analgesia since studies have shown, other than
the intravenous route, its efficacy after intramuscular and
oral administration [23, 24]. Also its formulation is stable at
room temperature with no need of special storage conditions
and produces general anaesthesia within 30–60 seconds that
lasts 10 to 15 minutes with ability to use repeated 1–3mg/min
boluses for maintenance which has made it easy to use in
emergency prehospital care [25].
This obstetrics study was a pioneer ketamine RCT in
MNRTH to show ketamine’s potential as a postoperative
adjunct to analgesia and was undertaken because globally
postoperative pain remains an issue even in first world
systems despite wide knowledge, new analgesics, and delivery
techniques [2].
Our findings of 30-minute extension to time to break-
through pain could in part be because we considered the
lower threshold cutoff for pain as 3 on numerical scale
unlike similar studies that used a higher threshold at the
moderate pain level (4 for NRS and <2 for VAS) as a point of
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intervention [18], or because we gave it at preincision rather
than at end of surgery hence observing a “shortened” time to
next analgesic. We thus recommend more ketamine studies
addressing and incorporating our perceived shortcomings
that affected this study’s time variable. However clinically in
this study, ketamine was tolerated well among women and
neonates with insignificant adverse effects and had similar
outcomes to other studies [21].
4.1. Study Limitations. Limitations of this study are the
following: low powered study unable to give statistically
significant finings, inability to draw a solid conclusion for
maternal and neonatal safety without monitoring ketamine
serum levels as liquid chromatography- (LC-) tandem mass
spectrometry for its metabolites were not available and
would have been a steep cost for self-funded research, and
failure to capture ketamine’s long-term effects, preferably in
postnatal clinic at 6 weeks as per MNRTH protocol, because
we premised it on the subanesthetic dose used and study
terminated at 48 hours postoperatively.
5. Conclusion
For Caesarean delivery Mulago, preincision intravenous
ketamine (0.25mg/kg) given after spinal anesthetic had a
good safety profile and gave 30-minute prolongation to
postoperative analgesia requirement with reduced 24 hr pain
scores and findings are generalizable as biological inter-
ventions are usually similar across populations. However
we recommend larger studies to further explore ketamine
benefits and get the right dose estimate for prolongation of
postoperative pain.
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